



Patent Foramen Ovale And Stroke

8th Annual Oregon Stroke Network Conference
September 27, 2013
Bend, Oregon

William J. Powers, MD
H. Houston Merritt Distinguished Professor and Chair
Department of Neurology
University of North Carolina School of Medicine
Chapel Hill, NC

Certified as a Comprehensive Stroke Center
by The Joint Commission and AHA/ASA

Financial Disclosures for William J. Powers, M.D.

Salary and Research Support:
National Institutes of Health
University of North Carolina

Additional personal income from honoraria for lectures to academic institutions and professional societies.

My wife provides independent consultant services to academia.

We have no personal financial relationships with any for-profit entities.

Unapproved Drugs and Devices

The United States Food and Drug Administration has not approved:

- the STARFLEX Closure System for PFO closure
- the Amplatzer occluder for PFO closure

Patent Foramen Ovale (PFO)

- **PFO has been associated with stroke, particularly in young patients with cryptogenic stroke, in studies from hospital echocardiography laboratories but not in studies conducted in the general population**
- The risk of recurrent stroke on medical therapy is very low and may be lower than in those without PFO
- PFO size and coincident atrial septal aneurysm (ASA) are not consistently related to recurrence
- Warfarin is not better than aspirin in preventing recurrence, inconsistent with a venous thrombosis paradoxical embolism mechanism

Association of PFO with Stroke

	Prevalence in Stroke	Prevalence in Controls	Source
Lechat, et al <small>(NEJM 1988; 318:1148-52)</small>	40%	10%	Hospital Echo Lab
Petty, et al <small>(Mayo Clin Proc 2006; 81: 602-608)</small>	24.8%	24.7%	Community

Patent Foramen Ovale (PFO)

- PFO has been associated with stroke, particularly in young patients with cryptogenic stroke, in studies from hospital echocardiography laboratories but not in studies conducted in the general population
- **The risk of recurrent stroke on medical therapy is very low and may be lower than in those without PFO**
- PFO size and coincident atrial septal aneurysm (ASA) are not consistently related to recurrence
- Warfarin is not better than aspirin in preventing recurrence, inconsistent with a venous thrombosis paradoxical embolism mechanism

Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale on Anti-platelet Therapy

(Mas J-L, et al: NEJM 2001; 345: 1740-1746)

RECURRENT STROKE

	<u>No PFO or ASA</u>	<u>PFO only</u>
2 years	3.7% (1.6 - 5.8)	1.8 % (.05 - 3.6)
4 years	4.2% (1.8 - 6.6)	2.3% (0.3 – 9.3)

ASA – atrial septal aneurysm

Patent Foramen Ovale (PFO)

- PFO has been associated with stroke, particularly in young patients with cryptogenic stroke, in studies from hospital echocardiography laboratories but not in studies conducted in the general population
- The risk of recurrent stroke on medical therapy is very low and may be lower than in those without PFO
- **PFO size and coincident atrial septal aneurysm (ASA) are not consistently related to recurrence**
- Warfarin is not better than aspirin in preventing recurrence, inconsistent with a venous thrombosis paradoxical embolism mechanism

Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale and Atrial Septal Aneurysm on Anti-platelet Therapy

(Mas J-L, et al: NEJM 2001; 345: 1740-1746)


RECURRENT STROKE

	No PFO or ASA	PFO + ASA
2 years	3.7% (1.6 - 5.8)	4.0% (0.0 - 9.4)
4 years	4.2% (1.8 - 6.6)	15.2% (1.8 - 33.4)

ASA – atrial septal aneurysm. No events in 10 patients with ASA alone

Stroke recurrence by Right-Left Shunt (RLSh) magnitude and presence of Atrial Septal Aneurysm (ASA) in the whole and younger (< 55) populations.

Mean follow-up 2.0 ± 1.1 yrs




CODICIA Serena J et al. Stroke 2008;39:3131-3136

Patent Foramen Ovale (PFO)

- PFO has been associated with stroke, particularly in young patients with cryptogenic stroke, in studies from hospital echocardiography laboratories but not in studies conducted in the general population
- The risk of recurrent stroke on medical therapy is very low and may be lower than in those without PFO
- PFO size and coincident atrial septal aneurysm (ASA) are not consistently related to recurrence
- **Warfarin is not better than aspirin in preventing stroke recurrence, inconsistent with a venous thrombosis-paradoxical embolism mechanism**

Effect of Medical Treatment on Subsequent Ischemic Stroke and Death for Patients with Stroke and PFO

(Homma, S et al: Circulation 2002; 105:2625-2631)




3 Randomized Controlled Trials of Mechanical Closure of Patent Foramen Ovale to Prevent Recurrent Stroke

- STARFlex device
 - CLOSURE I
- Amplatzer PFO occluder
 - RESPECT
 - PC Trial

CLOSURE I

Furlan, et al: N Engl J Med 2012; 366:991-9




- At two years, there was no difference between the two groups in the primary combined endpoint of stroke, TIA, and neurological death plus all death within 30 days
 - Device 5.5% (23 events)
 - Medical only 6.8% (29 events), p=0.37
- For Stroke alone
 - Device 2.9% (12)
 - Medical only 3.1% (13), p=0.77

Lost-to follow-up

Closure	1.7 % (8/447)
Medical only	0.6% (3/462)

CLOSURE I


Furlan, et al: N Engl J Med 2012; 366:991-9



- Neither the degree of right-to-left shunt nor the presence of atrial septal aneurysm identified a subgroup that benefitted from PFO closure.
- Certain serious adverse events were more common in the closure group:
 - Major vascular procedural complications (3.2% vs 0%, p < .001)
 - Atrial fibrillation (5.7% vs 0.7%, p < .001)


CLOSURE I

Furlan, et al: N Engl J Med 2012; 366:991-9




NO Benefit for “Medical Failures”

Subgroup	Closure no. of patients/haz no. (%)	Medical Therapy no. of patients/haz no. (%)	Hazard Ratio (95% CI)	P Value	P Value for Interaction
Overall modified intention-to-treat population	22/400 (5.4)	29/451 (6.5)	0.78 (0.44-1.35)	0.37	
Baseline medication					0.65
None	6/13 (0)	2/38 (5.3)			
Aspirin alone	15/238 (6.3)	16/252 (6.3)	0.79 (0.39-1.59)	0.50	
Warfarin alone	1/23 (4.3)	8/111 (7.2)	0.52 (0.06-4.12)	0.58	
Aspirin plus warfarin	6/72 (8.3)	2/40 (5.0)	3.59 (0.52-7.89)	0.17	



RESPECT

Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Standard of Care Treatment
N Engl J Med 2013;368:1092-100




- At a mean follow-up of 2.6 years, there was no significant difference between the two groups in the primary combined endpoint of death within 45 days or ischemic stroke
 - Device group – 9 strokes
 - Medical only group – 16 strokes

Hazard ratio 0.49 (95% CI .22 – 1.11), p= .08
- Almost five times more had incomplete follow-up than had endpoints

Closure	8.6 % (43/499)
Medical only	16.4% (79/481)

RESPECT


Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Standard of Care Treatment
N Engl J Med 2013;368:1092-100



- Both a substantial degree of right-to-left shunt and the presence of atrial septal aneurysm favored the PFO closure group in multiple subgroup analyses.
- Serious adverse events were uncommon in the closure group:
 - Major vascular procedural complications (0.8% vs 0%, p < .124)
 - Atrial fibrillation (0.6% vs 0.6%, p =1)

The PC Trial

N Engl J Med 2013; 368:1083-1091



- At a mean follow-up of 4 years, there was no significant difference between the two groups in the primary combined endpoint of any death, non-fatal stroke, TIA or peripheral embolism
 - Device Group - 7 events
 - Medical only Group - 11 events

Hazard Ratio 0.63 (95%CI .24 – 1.62) , p=.34
- For Stroke
 - Device group – 1 stroke
 - Medical only group – 5 strokes

Hazard ratio 0.20 (95% CI .02 – 1.72), p= .14
- Four times more had incomplete follow-up than had endpoints

Closure	15% (31/204)
Medical only	20% (42/210)

Randomized Controlled Trials of Mechanical Closure of Patent Foramen Ovale to Prevent Recurrent Stroke

- All three trials all individually failed to achieve primary endpoint
- What about a meta-analysis?

Meta-analysis of 3 PFO Closure RCTs on Recurrent Stroke

Kitsios, et al. Stroke DOI 10.1161/STROKEAHA.113.001773

	Device	Medical Only	Risk Ratio (95% CI)
CLOSURE I	12/447	13/462	0.90 (.41,1.98)
RESPECT	9/499	16/481	0.49 (.21, 1.11)
PC	1/204	5/210	0.14 (.02,1.17)
Pooled RCTs	Random Effects Model (Trial Heterogeneity)		0.55 (.26,1.18) NOT SIGNIFICANT

... but is it appropriate to lump data from two different devices?

Meta-analysis of 2 PFO Closure RCTs with Amplatzer Device on Recurrent Stroke

Kitsios, et al. Stroke DOI 10.1161/STROKEAHA.113.001773

	Device	Medical Only	Risk Ratio (95% CI)
RESPECT	9/499	16/481	0.49 (.21, 1.11)
PC	1/204	5/210	0.14 (.02,1.17)
Pooled RCTs	Random Effects Model (Trial Heterogeneity)		0.38 (.14,1.02) NOT SIGNIFICANT
Pooled RCTs	Fixed Effect Model (No Trial Heterogeneity)		0.41 (.19, .88) SIGNIFICANT

However, these 2 trials had incomplete follow-up patients > 4 x the total endpoints.
One additional stroke in the lost to follow-up device patients would render the fixed effects model not statistically significant

Mechanical Closure of PFO to Prevent Recurrent Stroke Where are we?

- The importance of PFO as a cause of stroke is marginal at best
- The risk of recurrent stroke on anti-platelet therapy is very low
- Studies that show a trend toward benefit of closure have serious methodological problems
- The long-term safety of the implanted closure devices is unknown

Mechanical Closure of PFO to Prevent Recurrent Stroke

MY ASSESSMENT OF THE DATA

- The evidence is insufficient at this time to recommend mechanical closure of PFO to prevent recurrent stroke, even for those with recurrent events on medical therapy

